Medical devices, healthcare technology and the business of care
PMA SUPPLEMENT · P150013/S035

PD-L1 IHC 22C3 pharmDx

Agilent Technologies, Inc. · Decision date Sep 11, 2026

MEDTECHLEDGER EXPLANATIONP150013/S035

What did the FDA decide?

The FDA recorded a 30-Day Notice decision, OK30, dated 2026-09-11 for supplement P150013/S035 to Agilent Technologies, Inc.'s PD-L1 IHC 22C3 pharmDx, an immunohistochemistry antibody assay for programmed death-ligand 1 under product code PLS in the pathology specialty. The recorded statement covers approval of manufacturing process and equipment changes for filling and capping.

This action concerns the manufacturing process rather than a new approval of the assay itself; the supplement reason is listed as a process change involving manufacturer, sterilizer, packager or supplier. The source record does not identify which filling or capping equipment changed, the sites involved, or any supporting validation data, and no linked FDA documents are included. Whether the change affects assay performance or labeling cannot be determined from this record.

The decision date is in the future relative to typical publication timelines, and the record provides no clinical, analytical or legal detail beyond the fields shown. Readers should treat the scope as limited to the stated manufacturing change.

FDA approval order statement

approval of manufacturing process and equipment changes for filling and capping
Regulatory pathway
PMA supplement
Supplement type
30-Day Notice
Clinical specialty
Pathology
Decision date
Sep 11, 2026
FDA change category
Process Change - Manufacturer/Sterilizer/Packager/Supplier

FDA source record · MedtechLedger’s explanation describes the recorded change.

Regulatory record facts

Identifier
P150013/S035
Regulatory pathway
PMA supplement
Product code
PLS
Decision code
OK30
Decision date
Sep 11, 2026
Source update
Nov 9, 2026
Original record
Open FDA source record

About this medical device

FDA device category: Immunohistochemistry assay, antibody, programmed death-ligand 1.

Product code
PLS
FDA device class
3

For the original device and its historical approval scope, see PMA P150013. Subsequent supplements may change the device or its indications.

FDA decision timeline

  1. P150013 · Original PMA

    PD-L1 IHC 22C3 PHARMDX

  2. P150013/S035 received

    Application receipt date recorded by FDA.

  3. P150013/S035 · FDA decision

    30-Day Notice

Timeline entries are records held by MedtechLedger for P150013. View FDA’s full supplement list.

Related devices and submissions

Same PMA: P150013

Product / regulatory recordCompanyPathwayDecision dateSource
Agilent Technologies, Inc.PMA approvalOct 2, 2015FDA
Agilent Technologies, Inc.PMA supplementSep 21, 2026FDA

Explore the linked device profile

Regulatory context

A PMA supplement records a change to a device with an existing premarket approval. The supplement’s approval applies to the change described in that submission.

Read our guide to FDA clearance and approval · FDA’s explanation of this pathway

Manufacturer intelligence

Agilent Technologies, Inc.

Headquarters
Not reported
Brand website
Not reported
FDA applicant address
5301 Stevens Creek Blvd., Santa Clara, CA, 95051

Sources and methodology

FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.

How we use FDA records